SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment

@article{Lane1998SSRIInducedES,
  title={SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment},
  author={Roger M. Lane},
  journal={Journal of Psychopharmacology},
  year={1998},
  volume={12},
  pages={192 - 214}
}
  • R. Lane
  • Published 1998
  • Psychology, Medicine
  • Journal of Psychopharmacology
The selective serotonin reuptake inhibitors (SSRIs) may occasionally induce extrapyramidal side-effects (EPS) and/or akathisia.This maybe a consequence of serotonergically-mediated inhibition of the dopaminergic system. Manifestations of these effects in patients may depend on predisposing factors such as the presence of psychomotor disturbance, a previous history of drug-induced akathisia and/or EPS, concurrent antidopaminergic and/or serotonergic therapy, recent monoamine oxidase inhibitor… Expand
Treatment of Neuroleptic-Induced Akathisia With the 5-HT2A Antagonist Trazodone
TLDR
Trazodone is found to be a beneficial and relatively safe medication for the treatment of antipsychotic medication-induced akathisia and some improvement was noted in symptomatology of anxiety, depression, and psychosis. Expand
Extrapyramidal Symptoms Associated with Selective Serotonin Reuptake Inhibitors
TLDR
Anatomical, physiological and pharmacological relationships between SSRI-induced movement disorders includes avoidance of SSRI use, dose reduction or discontinuation of the offending drug and the same measures that are used for treating antipsychotic- induced movement disorders. Expand
Escitalopram-induced Parkinsonism.
TLDR
It is shown that drug-induced Parkinsonism may persist or remit slowly despite prompt discontinuation of the offending drug, and some patients may require medications temporarily to relieve symptoms. Expand
Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists
TLDR
Accumulating evidence during the last two decades indicates that agents with marked postsynaptic serotonin 5-HT2a receptor antagonism may represent a new class of potential anti-akathisia remedies and low-dose mirtazapine has demonstrated the most compelling evidence for therapeutic efficacy. Expand
Efficacy of carbamazepine against neuroleptic-induced akathisia in treatment with perospirone: case series
TLDR
Three cases of schizophrenia whose neuroleptic-induced akathisia did not respond to representative anti-akathisian drugs showed a marked improvement of it without worsening of psychotic symptoms during a combination treatment with carbamazepine and perospirone, a serotonin-dopamine antagonist developed in Japan. Expand
Escitalopram-induced extrapyramidal symptoms
TLDR
A case of escitalopram-induced EPS is reported to increase clinical awareness about this rare presentation and to increaseclinical awareness about the incidence of EPS among SSRIs. Expand
Selective serotonin reuptake inhibitor-induced akathisia.
TLDR
Pharmacists can play an active role in recognizing akathisia by being aware of its characteristics, conducting a thorough medication history to identify causative agents, and using BARS to evaluate patients. Expand
Trazodone as an Alternative Treatment for Neuroleptic-Associated Akathisia
TLDR
It is suggested that trazodone might be an effective and relatively safe drug in the treatment of neuroleptic-associated akathisia. Expand
Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics
TLDR
Knowledge of the differences that exist among the SSRIs in respect of tolerability and safety will aid physicians in the selection of the most beneficial treatment strategy for their patients, as well as translating into significantly different economic outcomes within the group. Expand
Do SSRI Antidepressants Increase The Risk of Extrapyramidal Side Effects In Patients Taking Antipsychotics?
TLDR
SSRIs did not appear to potentiate the occurrence of EPS in patients using antipsychotics, and a retrospective cohort analysis of the cross-sectional data that were collected found no significant differences. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 302 REFERENCES
Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.
TLDR
To reduce the occurrence, morbidity, and mortality of the serotonin syndrome, it must be both prevented by prudent pharmacotherapy and given prompt recognition when it is present. Expand
Extrapyramidal Side‐Effects in Elderly Patients Exposed to Selective Serotonin Reuptake Inhibitors
TLDR
The prevalence of SSRI‐associated EPSE may be higher in the elderly, and in particular in medically ill patients with underlying brain disease, and the adverse effect resolved completely after discontinuation of the SSRI. Expand
Fluoxetine-induced akathisia: clinical and theoretical implications.
TLDR
The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetsia and tricyclic antidepressant-induced "jitteriness" may be identical. Expand
Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors
  • R. Lane
  • Biology, Medicine
  • International clinical psychopharmacology
  • 1996
TLDR
Knowing the substrates and inhibitors of CYP isoenzymes may help clinicians to anticipate and avoid pharmacokinetic drug interactions and may better define rational prescribing practices. Expand
Treatment of the serotonin syndrome with cyproheptadine.
TLDR
The role of specific serotonin receptor antagonists such as cyproheptadine in the treatment of the serotonin syndrome remains to be delineated and its use should be considered an adjunct to supportive care. Expand
The SSRIs: advantages, disadvantages and differences
The highly specific mechanism of action of the selective serotonin re-uptake inhibitors (SSRIs) confers advantages on this group, relative to other classes of antidepressant, and thus represents aExpand
Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
TLDR
Results indicate that genetically impaired CYP2D6 metabolism may be a contributing factor for the development of persistent TD. Expand
Adverse consequences of fluoxetine-MAOI combination therapy.
The authors describe two series of patients: 12 treated simultaneously with fluoxetine and a monoamine oxidase inhibitor and 6 patients started on treatment with an MAOI 10 days or more afterExpand
The Identification and Management of Drug-Induced Akathisia
SummaryAkathisia is a common and clinically important adverse effect of antipsychotic and some other psychotropic drugs, which has until recently been neglected by researchers and clinicians. ItExpand
Akathisia, suicidality, and fluoxetine.
TLDR
A heuristic "Four Neuron Model of the Extrapyramidal Motor System" is proposed in which increased serotonin activity, by inhibiting the nigrostriatal dopamine tract, is capable of inducing extrapYramidal side effects. Expand
...
1
2
3
4
5
...